About C₂N Diagnostics
C₂N Diagnostics is a company based in St. Louis (United States) founded in 2000 by Ilana Fogelman and Joel B Braunstein.. C₂N Diagnostics has raised $35 million across 13 funding rounds from investors including Eisai, Samsung Bioepis and Samsung C&T. C₂N Diagnostics offers products and services including PrecivityAD Test, PrecivityAD2 Test, and Precivity-ApoE Test. C₂N Diagnostics operates in a competitive market with competitors including Todos Medical, ADmit Therapeutics, ALZpath, Amydis Diagnostics and SYNAPS Dx, among others.
- Headquarter St. Louis, United States
- Founders Ilana Fogelman, Joel B Braunstein
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$35 M (USD)
in 13 rounds
-
Latest Funding Round
$10 M (USD), Debt – Conventional
May 12, 2025
-
Investors
Eisai
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of C₂N Diagnostics
C₂N Diagnostics offers a comprehensive portfolio of products and services, including PrecivityAD Test, PrecivityAD2 Test, and Precivity-ApoE Test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Assesses brain amyloid pathology for Alzheimer's diagnosis
Evaluates Alzheimer's risk in patients with cognitive impairment
Determines apolipoprotein E status for treatment decisions
Funding Insights of C₂N Diagnostics
C₂N Diagnostics has successfully raised a total of $35M across 13 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $10 million completed in May 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 13
- Last Round Debt – Conventional — $10.0M
-
First Round
First Round
(22 Sep 2009)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2025 | Amount | Debt – Conventional - C₂N Diagnostics | Valuation |
investors |
|
| Mar, 2025 | Amount | Unspecified - C₂N Diagnostics | Valuation |
investors |
|
| Oct, 2024 | Amount | Grant - C₂N Diagnostics | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in C₂N Diagnostics
C₂N Diagnostics has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include Eisai, Samsung Bioepis and Samsung C&T. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in promising startups.
|
Founded Year | Domain | Location | |
|
Contract development and manufacturing for biologics are provided.
|
Founded Year | Domain | Location | |
|
Construction, trading, fashion, and resort services are provided globally.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by C₂N Diagnostics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - CN Diagnostics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
C₂n Diagnostics Comparisons
Competitors of C₂N Diagnostics
C₂N Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Todos Medical, ADmit Therapeutics, ALZpath, Amydis Diagnostics and SYNAPS Dx, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Todos Medical is focused on developing diagnostic blood tests.
|
|
| domain | founded_year | HQ Location |
Early Alzheimer's detection is facilitated through blood-based epigenetic diagnostics.
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions for Alzheimer's disease are developed using blood-based biomarkers.
|
|
| domain | founded_year | HQ Location |
Developer of diagnostics test for detection of Alzheimer's disease
|
|
| domain | founded_year | HQ Location |
Developer of a diagnostic test to detect Alzheimer's disease
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on C₂n Diagnostics
Frequently Asked Questions about C₂N Diagnostics
When was C₂N Diagnostics founded?
C₂N Diagnostics was founded in 2000 and raised its 1st funding round 9 years after it was founded.
Where is C₂N Diagnostics located?
C₂N Diagnostics is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Who is the current CEO of C₂N Diagnostics?
Joel B Braunstein is the current CEO of C₂N Diagnostics. They have also founded this company.
Is C₂N Diagnostics a funded company?
C₂N Diagnostics is a funded company, having raised a total of $35M across 13 funding rounds to date. The company's 1st funding round was a Grant of $15M, raised on Sep 22, 2009.
What does C₂N Diagnostics do?
CN Diagnostics was founded in 2000 in St. Louis, United States, within the biotechnology sector. Alzheimers disease diagnostics and therapies are developed, including the PrecivityAD blood test used to assess amyloid plaques in patients with cognitive impairment. Bioanalytical services are also provided to pharmaceutical and biotechnology firms for research support. Operations focus on advancing neurological disorder solutions through clinical and analytical tools.
Who are the top competitors of C₂N Diagnostics?
C₂N Diagnostics's top competitors include ADmit Therapeutics, Todos Medical and NeuroDex.
What products or services does C₂N Diagnostics offer?
C₂N Diagnostics offers PrecivityAD Test, PrecivityAD2 Test, and Precivity-ApoE Test.
Who are C₂N Diagnostics's investors?
C₂N Diagnostics has 8 investors. Key investors include Eisai, Samsung Bioepis, Samsung C&T, HHS, and Samsung Venture Investment.